 Hugo Escobar
Concepts (114)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 3 | 2021 | 18 | 0.820 |
Why?
| | Lung Diseases | 3 | 2017 | 23 | 0.640 |
Why?
| | Aminophenols | 2 | 2018 | 2 | 0.450 |
Why?
| | Quinolones | 2 | 2018 | 2 | 0.450 |
Why?
| | Benzodioxoles | 2 | 2018 | 2 | 0.450 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2018 | 3 | 0.450 |
Why?
| | Pseudomonas Infections | 1 | 2021 | 7 | 0.390 |
Why?
| | Bronchopulmonary Dysplasia | 3 | 2018 | 39 | 0.360 |
Why?
| | Pyrrolidines | 1 | 2018 | 1 | 0.320 |
Why?
| | Chloride Channel Agonists | 1 | 2018 | 1 | 0.320 |
Why?
| | Pyrazoles | 1 | 2018 | 3 | 0.320 |
Why?
| | Indoles | 1 | 2018 | 3 | 0.320 |
Why?
| | Nitric Oxide | 2 | 2018 | 6 | 0.300 |
Why?
| | Respiratory Insufficiency | 2 | 2018 | 13 | 0.300 |
Why?
| | Humans | 11 | 2023 | 6915 | 0.230 |
Why?
| | Respiratory Function Tests | 3 | 2018 | 16 | 0.220 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2023 | 11 | 0.220 |
Why?
| | Hospitalization | 2 | 2023 | 217 | 0.210 |
Why?
| | Forced Expiratory Volume | 3 | 2021 | 10 | 0.210 |
Why?
| | Lung | 2 | 2018 | 65 | 0.180 |
Why?
| | Infant, Premature, Diseases | 2 | 2018 | 22 | 0.180 |
Why?
| | Infant, Newborn | 6 | 2023 | 825 | 0.180 |
Why?
| | Male | 8 | 2018 | 3383 | 0.180 |
Why?
| | Administration, Inhalation | 3 | 2021 | 19 | 0.170 |
Why?
| | Exercise Tolerance | 1 | 2018 | 8 | 0.160 |
Why?
| | Bronchodilator Agents | 1 | 2018 | 11 | 0.160 |
Why?
| | Bronchitis | 1 | 2018 | 1 | 0.160 |
Why?
| | Microsurgery | 1 | 2018 | 1 | 0.160 |
Why?
| | Mycobacterium avium Complex | 1 | 2018 | 1 | 0.160 |
Why?
| | Laser Therapy | 1 | 2018 | 4 | 0.160 |
Why?
| | Mycobacterium avium-intracellulare Infection | 1 | 2018 | 2 | 0.160 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2018 | 12 | 0.160 |
Why?
| | Antitubercular Agents | 1 | 2018 | 7 | 0.160 |
Why?
| | Female | 7 | 2018 | 3563 | 0.150 |
Why?
| | Intermittent Positive-Pressure Ventilation | 1 | 2017 | 1 | 0.150 |
Why?
| | Interactive Ventilatory Support | 1 | 2017 | 1 | 0.150 |
Why?
| | Prospective Studies | 3 | 2021 | 532 | 0.150 |
Why?
| | Energy Metabolism | 1 | 2017 | 28 | 0.150 |
Why?
| | Fluorescent Dyes | 1 | 2017 | 7 | 0.140 |
Why?
| | Exhalation | 1 | 2017 | 1 | 0.140 |
Why?
| | Flow Cytometry | 1 | 2017 | 30 | 0.140 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 23 | 0.140 |
Why?
| | Tracheostomy | 1 | 2017 | 14 | 0.140 |
Why?
| | Aminopyridines | 1 | 2015 | 2 | 0.130 |
Why?
| | Steroids | 1 | 2013 | 16 | 0.110 |
Why?
| | Severity of Illness Index | 3 | 2023 | 153 | 0.110 |
Why?
| | Infant, Extremely Premature | 1 | 2013 | 12 | 0.110 |
Why?
| | Virus Diseases | 1 | 2013 | 16 | 0.110 |
Why?
| | Bacterial Infections | 1 | 2013 | 27 | 0.110 |
Why?
| | Double-Blind Method | 2 | 2018 | 45 | 0.110 |
Why?
| | Infant | 4 | 2023 | 1464 | 0.110 |
Why?
| | Adolescent | 3 | 2023 | 2235 | 0.100 |
Why?
| | Respiratory Tract Infections | 1 | 2013 | 85 | 0.100 |
Why?
| | Mutation | 2 | 2018 | 213 | 0.100 |
Why?
| | Plethysmography | 1 | 2011 | 5 | 0.100 |
Why?
| | Oscillometry | 1 | 2011 | 2 | 0.100 |
Why?
| | Spirometry | 1 | 2011 | 7 | 0.100 |
Why?
| | Respiration | 1 | 2011 | 5 | 0.100 |
Why?
| | Tobramycin | 1 | 2021 | 3 | 0.100 |
Why?
| | Azithromycin | 1 | 2021 | 5 | 0.100 |
Why?
| | Infant, Premature | 3 | 2018 | 84 | 0.100 |
Why?
| | Pseudomonas aeruginosa | 1 | 2021 | 7 | 0.100 |
Why?
| | Child, Preschool | 2 | 2018 | 1600 | 0.100 |
Why?
| | Young Adult | 2 | 2018 | 657 | 0.090 |
Why?
| | Acids | 1 | 2010 | 1 | 0.090 |
Why?
| | Pepsin A | 1 | 2010 | 1 | 0.090 |
Why?
| | Mucin-5B | 1 | 2010 | 1 | 0.090 |
Why?
| | Ear, Middle | 1 | 2010 | 2 | 0.090 |
Why?
| | Gene Expression | 1 | 2010 | 65 | 0.080 |
Why?
| | Adult | 2 | 2018 | 1187 | 0.080 |
Why?
| | Sweat | 1 | 2018 | 1 | 0.080 |
Why?
| | Chlorides | 1 | 2018 | 4 | 0.080 |
Why?
| | Drug Combinations | 1 | 2018 | 20 | 0.080 |
Why?
| | Anti-Bacterial Agents | 1 | 2021 | 251 | 0.080 |
Why?
| | Cells, Cultured | 1 | 2018 | 81 | 0.080 |
Why?
| | Alleles | 1 | 2018 | 215 | 0.070 |
Why?
| | Genotype | 1 | 2018 | 410 | 0.070 |
Why?
| | Reproducibility of Results | 2 | 2017 | 201 | 0.070 |
Why?
| | Child | 3 | 2023 | 3393 | 0.070 |
Why?
| | Follow-Up Studies | 2 | 2018 | 302 | 0.060 |
Why?
| | Retrospective Studies | 2 | 2023 | 1300 | 0.060 |
Why?
| | Hospital Mortality | 1 | 2023 | 21 | 0.050 |
Why?
| | Mice | 2 | 2017 | 345 | 0.050 |
Why?
| | Animals | 2 | 2017 | 657 | 0.050 |
Why?
| | Bronchoscopy | 1 | 2018 | 7 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 77 | 0.040 |
Why?
| | Respiratory Rate | 1 | 2017 | 3 | 0.040 |
Why?
| | Oxygen | 1 | 2017 | 14 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 117 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2017 | 36 | 0.040 |
Why?
| | Gestational Age | 1 | 2017 | 62 | 0.040 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2017 | 35 | 0.040 |
Why?
| | Missouri | 1 | 2017 | 80 | 0.040 |
Why?
| | Protein Stability | 1 | 2017 | 1 | 0.040 |
Why?
| | Breath Tests | 1 | 2017 | 10 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2017 | 339 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2015 | 35 | 0.030 |
Why?
| | Homozygote | 1 | 2015 | 20 | 0.030 |
Why?
| | Diuretics | 1 | 2013 | 4 | 0.030 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2013 | 3 | 0.030 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2013 | 10 | 0.030 |
Why?
| | ROC Curve | 1 | 2013 | 22 | 0.030 |
Why?
| | Logistic Models | 1 | 2013 | 85 | 0.030 |
Why?
| | Middle Aged | 1 | 2015 | 614 | 0.030 |
Why?
| | Prognosis | 1 | 2013 | 212 | 0.030 |
Why?
| | Cohort Studies | 1 | 2013 | 288 | 0.030 |
Why?
| | Risk Factors | 1 | 2013 | 485 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2010 | 19 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2010 | 22 | 0.020 |
Why?
| | Cell Survival | 1 | 2010 | 19 | 0.020 |
Why?
| | Up-Regulation | 1 | 2010 | 25 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 67 | 0.020 |
Why?
| | Cell Line | 1 | 2010 | 81 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2010 | 112 | 0.020 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|